Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

The UC10-4B9 antibody can enhance T cell co-stimulation by blocking CTLA-4 interactions with the B7 co-receptors, favoring CD28 interactions. Additional reported applications (for the relevant formats) include: immunoprecipitation¹, in vitro stimulation, in vitro and in vivo blocking^1-4 of ligand binding, and as ELISA capture antibody⁵. To reduce non-specific binding to cells bearing Fc-receptors, pre-incubation of cells with anti-mouse CD16/CD32, clone 93 (Cat. No. 101301/101302), is recommended prior to immunofluorescent staining. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (Cat. No. 106306) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated anti-Armenian hamster IgG (Cat. No. 405501) second step, followed by SAv-PE (Cat. No. 405204)). The Ultra LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 106327).

1. Walunas TL, et al. 1994. Immunity 1:405. (Block, IP)
2. Cilio CM, et al. 1998. J. Exp. Med. 188:1239. (Block)
3. Issazadeh S, et al. 1999. J. Immunol. 162:761. (Block)
4. McCoy K, et al. 1997. J. Exp. Med. 186:183. (Block)
5. Hsu HC, et al. 2007. J. Immunol. 178:5357. (ELISA Capture)
6. Sugita S, et al. 2010. Invest. Ophthalmol. Vis. Sci. 51:5783. PubMed

1. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
2. Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed
3. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
4. Denk D, et al. 2022. Immunity. 55:2059. PubMed
5. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
6. Shi B, et al. 2018. J Immunol. 200:586. PubMed
7. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
8. Sugita S, et al. 2010. Invest Ophthalmol Vis Sci. 51:5783. PubMed
9. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
10. Alikhan M, et al. 2016. J Am Soc Nephrol. 27: 706 - 714. PubMed
11. DeLong JH, et al. 2019. Immunohorizons. 3:13. PubMed
12. Thauland T, et al. 2014. J Immunol. 193:5894. PubMed
13. Singh K, et al. 2015. Sci Rep. 14:7767. PubMed
14. Wei SC, et al. 2020. Cancer Discov. . PubMed
15. An J, et al. 2022. iScience. 25:103570. PubMed
16. Xu L et al. 2017. Immunity. 47(3):538-551 . PubMed
17. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
18. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
19. Ren J, et al. 2019. PLoS Biol. 17:e3000270. PubMed
20. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
21. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
22. Andersen L, et al. 2020. Cell Reports. 29(13):4447-4459.e6.. PubMed
23. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
24. Benci JL et al. 2019. Cell. 178(4):933-948 . PubMed
25. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
26. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
27. Elliot TAE, et al. 2021. Immunity. 54:2481. PubMed
28. Zhang GL, et al. 2020. Matrix Biol. 93:25. PubMed
29. Hu J, et al. 2022. J Immunother Cancer. 10:. PubMed
30. Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed
31. Li J, et al. 2021. Cell Rep. 37:110124. PubMed
32. Rinaldi S, et al. 2021. PLoS Pathog. 17:e1009533. PubMed
33. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
34. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
35. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
36. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed

Activated T cells and B cells

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Allison JP, et al. 1995. Science 270:932.
3. Waterhouse P, et al. 1995. Science 270:985.
4. Linsley PS, et al. 1991. J. Exp. Med. 174:561.